약물 관련 급성 신장 손상에 대한 다병원 전자 결정 지원 (MEnD-AKI)
약물 관련 급성 신장 손상에 대한 다병원 전자 결정 지원(MEnD-AKI)
This study is a randomized controlled trial at eight hospitals within the University of Pittsburgh Medical Center-UPMC system. The project will assess the efficacy of a clinical surveillance system augmented with near real-time predictive analytics to support a pharmacist-led intervention delivered to attending physicians (primary service) to reduce the progression and complications of drug-associated acute kidney injury (D-AKI) in hospitalized (non-ICU) adults.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Researchers will randomize 38 hospital service clusters to receive either: 1) a Cerner electronic medical record (EMR)-based AKI passive alert which is standard of care at UPMC: this alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management (Usual Care Arm); or 2) protocolized stage-based intervention delivered to the physician by a pharmacist for consideration and approval. The intervention uses an automated alerting system to identify patients: 1) receiving a high-risk drug or drug combination associated with D-AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with D-AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI per KDIGO criteria, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with D-AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. Additionally, the investigators will assess cost-effectiveness and physicians' perception of the pharmacist-led service.
The primary outcome is Major Adverse Kidney Events within 30 days of randomization (MAKE30), defined as defined as a composite of death, new kidney replacement therapy, or final serum creatinine ≥150% of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Key secondary outcomes include: progression of AKI from time of Level B intervention (first alert generated) to hospital discharge, AKI intensity (duration of AKI by all stages, duration of AKI stage 2, and duration of AKI stage 3), and nephrotoxic burden.
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Pennsylvania
-
Altoona, Pennsylvania, 미국, 16601
- UPMC Altoona
-
Farrell, Pennsylvania, 미국, 16121
- UPMC Horizon
-
McKeesport, Pennsylvania, 미국, 15132
- UPMC McKeesport
-
New Castle, Pennsylvania, 미국, 16105
- UPMC Jameson
-
Pittsburgh, Pennsylvania, 미국, 15232
- UPMC Shadyside
-
Pittsburgh, Pennsylvania, 미국, 15213
- UPMC Magee
-
Pittsburgh, Pennsylvania, 미국, 15213
- UPMC Presbyterian/Montefiore
-
Williamsport, Pennsylvania, 미국, 17701
- UPMC Williamsport
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Physician-subject Inclusion
- Physicians employed at UPMC hospital systems
- Attending physicians of record who care for patients across multiple units outside ICU/ED
- Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI
Physician-subject Exclusion
- Physicians of record who only care for ICU or ED patients
- Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients
- Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.)
Patient records used for primary outcome assessment: not enrolled as study participants. Patients are not prospectively enrolled, recruited, consented, or randomized in this study. The primary outcome is assessed using retrospectively obtained, de-identified data from electronic health records for eligible patient encounters associated with physicians assigned to randomized clusters.
Patient-subject Inclusion
- System alert identifying risk for AKI
- Patient has attending physician who is participating in the randomized clusters
- After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91
Patient-subject Exclusion
• Patients with end stage renal disease on admission, baseline eGFR <15, comfort measures only, or died before the intervention could be delivered
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Protocolized stage-based intervention
The intervention uses an automated alerting system to identify patients of enrolled physicians: 1) receiving a high-risk drug or drug combination associated with AKI and at low-risk for progression to either stage 2 AKI or stage 3 AKI (Level A) and 2) patients without AKI or stage 1 AKI receiving a high-risk drug or drug combination associated with AKI and at high risk for progression to either stage 2 AKI or stage 3 AKI, and patients with AKI stage 2 or stage 3 receiving a high-risk drug or drug combination associated with AKI or a medication that requires renal dose adjustment (Level B). This patient specific risk-profile will be coupled with recommendations for medication management and delivered to the physician by a pharmacist for consideration and approval. |
Pharmacy personnel will generate a general recommendation based on the AKI KDIGO management guidelines to the physician. The pharmacist will make nephrotoxic/renally eliminated medication management recommendations to the attending physician (or designee). Recommendations may include stopping or changing a drug, changing dose or schedule, ordering laboratory tests, taking no action, or other. The pharmacist will record details of the interaction with the physician and whether recommendations were accepted. |
|
활성 비교기: Usual Care
A Cerner EMR-based AKI passive alert which is standard of care at UPMC. |
Passive Cerner alert provides decision support within the EMR for the diagnosis and basic staging of AKI but without specific recommendations for management. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Patient Encounters With MAKE30 Among Patients Cared for by Enrolled Physicians
기간: up to 30 days
|
Composite of death, new kidney replacement therapy, or final serum creatinine greater than or equal to 150 percent of reference at the earliest of hospital discharge or 30 days from study enrollment, whichever occurs first. Patient encounters for the analyses reflects those meeting the criteria for the retrospective cohort. It was anticipated that patients would receive a considerable number of non-actionable alerts so ~ 3000 patients were included for the per protocol analysis to be impactful. |
up to 30 days
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Patient Encounters With AKI Progression Among Patients Cared for by Enrolled Physicians, From First Level B Alert to Hospital Discharge
기간: up to 30 days
|
Percent of high-risk patients without AKI at time of first level B alert who subsequently progress to maximum AKI severity stages 1, 2, or 3 before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-1 AKI at the time of level B alert who subsequently progress to maximum severity stages 2 or 3 AKI before hospital discharge or 30 days, whichever comes first. Percent of high-risk patients with stage-2 AKI at the time of level B alert who subsequently progress to maximum severity stage 3 AKI before hospital discharge or 30 days, whichever comes first. The machine learning algorithm operated silently for patient encounters in the Usual Care arm to determine whether they would have had a Level A or Level B alert, but no alert was delivered to study pharmacists and no intervention was received by study physicians. Patient encounters in the Usual Care arm represent the subset of patient encounters that would have had a qualifying Level B alert. |
up to 30 days
|
|
AKI Intensity: Duration of AKI for Patients at All Stages; Duration of AKI for Patients at Stage 2; Duration of AKI for Patients Stage 3
기간: up to 30 days
|
AKI intensity defined as the estimated marginal mean number of inpatient days spent in AKI overall at any stage and by each stage of AKI among patients cared for by enrolled physicians. |
up to 30 days
|
|
Nephrotoxic Burden
기간: up to 30 days
|
Drug.days* in both study arms for those drugs considered possible/probable, probable and definitely related to AKI in adult, non-ICU patients. *Drug.days calculation: each drug and each day of therapy increases the burden by 1 drug.day. |
up to 30 days
|
공동 작업자 및 조사자
협력자
협력자
수사관
수사관
- 수석 연구원: Azra Bihorac, MD, MS, University of Florida
- 수석 연구원: Sandra L Kane-Gill, PharmD, MS, University of Pittsburgh
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- STUDY20120008
- R01DK121730 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .